Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses.

× No keyword cloud information.

12 in total

Review 1. Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

Authors: Greg L Plosker; David P Figgitt
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

Review 2. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.

Authors: H Jiang; R-N Tang; J Wang
Journal: Eur J Clin Microbiol Infect Dis Date: 2013-04-10 Impact factor: 3.267

3. Managing Severe Community-Acquired Pneumonia Due to Community Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors: Jason C Kwong; Kyra Chua; Patrick G P Charles
Journal: Curr Infect Dis Rep Date: 2012-06 Impact factor: 3.725

4. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.

Authors: Allan J Walkey; Max R O'Donnell; Renda Soylemez Wiener
Journal: Chest Date: 2010-09-23 Impact factor: 9.410

Review 5. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.

Authors: Yan Wang; Yamin Zou; Jiao Xie; Taotao Wang; Xiaowei Zheng; Hairong He; Weihua Dong; Jianfeng Xing; Yalin Dong
Journal: Eur J Clin Pharmacol Date: 2014-10-30 Impact factor: 2.953

6. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus.

Authors: Aisling R Caffrey; Brian J Quilliam; Kerry L LaPlante
Journal: Antimicrob Agents Chemother Date: 2010-07-26 Impact factor: 5.191

Review 7. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

Authors: Matthew E Falagas; Konstantinos Z Vardakas
Journal: Drug Saf Date: 2008 Impact factor: 5.606

8. Aspiration pneumonia after stroke: intervention and prevention.

Authors: John R Armstrong; Benjamin D Mosher
Journal: Neurohospitalist Date: 2011-04

9. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

Authors: Ethan Rubinstein; Tahaniyat Lalani; G Ralph Corey; Zeina A Kanafani; Esteban C Nannini; Marcelo G Rocha; Galia Rahav; Michael S Niederman; Marin H Kollef; Andrew F Shorr; Patrick C Lee; Arnold L Lentnek; Carlos M Luna; Jean-Yves Fagon; Antoni Torres; Michael M Kitt; Fredric C Genter; Steven L Barriere; H David Friedland; Martin E Stryjewski
Journal: Clin Infect Dis Date: 2011-01-01 Impact factor: 9.079

Review 10. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.

Authors: Mathias W Pletz; O Burkhardt; T Welte
Journal: Eur J Med Res Date: 2010-11-30 Impact factor: 2.175